Abstract
Introduction: Αndrogenetic alopecia (Androgenetic Alopecia) is the most common hair disorder, affecting approximately 50% of men and women. A topical lotion that contains two patented formulas (Redensyl® and Sepicontrol A5®), has been introduced as an alternative approach to standard therapies for Androgenetic Alopecia.
Methods: Forty-four patients with Androgenetic Alopecia were randomized either to apply the active lotion or the vehicle, twice daily for 24 weeks. Subjects were evaluated at 0, 12, and 24 weeks by clinical examination, photographic documentation, quality of life evaluation (DLQI), and trichogram (anagen to telogen ratio).
Results: Forty-one patients, 18 males and 23 females, completed the study. Among patients receiving active treatment (n=26), 7.7% had great improvement, 73.1% had moderate improvement and 19.2% remained stable. The median self-assessment score increased from 4 at baseline to 6 at 24 weeks (p<0.001), while the DLQI improved from 4 to 3, respectively (p<0.001). The median anagen to telogen ratio increased from 2.25 to 4.00 to 6.02 at week 0, 12 and 24, respectively. No significant adverse events were reported.
Conclusion: This new topical active blend is effective in the treatment of Androgenetic Alopecia, with high degree of patients' satisfaction, improvement of quality of life, and an excellent safety profile. Thus, it may represent a useful alternative therapeutic approach for Androgenetic Alopecia. This article is protected by copyright. All rights reserved.
Link: https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.13734
Introduction: Αndrogenetic alopecia (Androgenetic Alopecia) is the most common hair disorder, affecting approximately 50% of men and women. A topical lotion that contains two patented formulas (Redensyl® and Sepicontrol A5®), has been introduced as an alternative approach to standard therapies for Androgenetic Alopecia.
Methods: Forty-four patients with Androgenetic Alopecia were randomized either to apply the active lotion or the vehicle, twice daily for 24 weeks. Subjects were evaluated at 0, 12, and 24 weeks by clinical examination, photographic documentation, quality of life evaluation (DLQI), and trichogram (anagen to telogen ratio).
Results: Forty-one patients, 18 males and 23 females, completed the study. Among patients receiving active treatment (n=26), 7.7% had great improvement, 73.1% had moderate improvement and 19.2% remained stable. The median self-assessment score increased from 4 at baseline to 6 at 24 weeks (p<0.001), while the DLQI improved from 4 to 3, respectively (p<0.001). The median anagen to telogen ratio increased from 2.25 to 4.00 to 6.02 at week 0, 12 and 24, respectively. No significant adverse events were reported.
Conclusion: This new topical active blend is effective in the treatment of Androgenetic Alopecia, with high degree of patients' satisfaction, improvement of quality of life, and an excellent safety profile. Thus, it may represent a useful alternative therapeutic approach for Androgenetic Alopecia. This article is protected by copyright. All rights reserved.
Link: https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.13734
